Accelr8's Stock Plummets after BD Declines Option on Bacterial Dx Tech | GenomeWeb

NEW YORK (GenomeWeb News) – Shares in Accelr8 plummeted nearly 30 percent today following news that Becton Dickinson has declined an option to license the company's rapid bacterial diagnostic system.

BD advised the company that it would decline an exclusive license option to the technology associated with an 18-month testing agreement it inked with Accelr8 in April 2008.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: genome sequencing study of Yakutian horses, tardigrade genome, and more.

A guest post at Retraction Watch discusses what funders can do to improve research reproducibility.

Researchers report in Nature this week that farming led to genomic adaptations in humans.

The FDA argues that it needs to evaluate the safety and efficacy of laboratory-developed tests, a proposal that divides Republicans.